降脂药物与不符合痴呆症标准的认知障碍风险，与载脂蛋白E状态的关系。

Lipid-lowering agents and the risk of cognitive impairment that does not meet criteria for dementia, in relation to apolipoprotein E status.

作者信息

Rockwood Kenneth, Howlett Susan, Fisk John, Darvesh Sultan, Tuokko Holly, Hogan David B, Wolfson Christina, McDowell Ian

机构信息

Division of Geriatric Medicine, Dalhousie University, Halifax, NS, Canada.

出版信息

Neuroepidemiology. 2007;29(3-4):201-7. doi: 10.1159/000111583. Epub 2007 Nov 27.

DOI:10.1159/000111583

PMID:18043005

Abstract

Lipid-lowering agents (LLAs) might lower the risk of dementia, but any impact on other forms of cognitive impairment is not clear. We examined LLAs in relation to cognitive impairment, no dementia (CIND) and apolipoprotein E4 status. In a case control study from the Canadian Study of Health and Aging, cases (n = 347) had developed CIND between the first and second study waves and controls (n = 693) had no cognitive impairment at either time. LLA use was associated with a lower odds of incident CIND in those <80 years of age (OR 0.37; 95% CI 0.15-0.93) but not for those aged >or=80 years (OR 0.56; 95% CI 0.15-2.10). The reduced risk was significant for statins but not for other LLAs. Adjusting for apolipoprotein E4 status did not change the point estimates of the ORs. The greatest impact of LLAs was seen in the CIND subtype circumscribed memory impairment.

摘要

降脂药物（LLAs）可能会降低患痴呆症的风险，但对其他形式的认知障碍的影响尚不清楚。我们研究了降脂药物与认知障碍、非痴呆型认知障碍（CIND）和载脂蛋白E4状态之间的关系。在加拿大健康与老龄化研究的一项病例对照研究中，病例组（n = 347）在第一次和第二次研究期间出现了CIND，对照组（n = 693）在两个时间点均无认知障碍。在年龄<80岁的人群中，使用LLAs与新发CIND的较低几率相关（比值比[OR] 0.37；95%置信区间[CI] 0.15 - 0.93），但在年龄≥80岁的人群中并非如此（OR 0.56；95% CI 0.15 - 2.10）。他汀类药物降低风险的作用显著，但其他LLAs并非如此。调整载脂蛋白E4状态并未改变OR的点估计值。LLAs对CIND亚型局限性记忆障碍的影响最大。